AI assistant
Glenmark Pharmaceuticals ltd — Capital/Financing Update 2018
Oct 9, 2018
62608_rns_2018-10-09_3215a04e-22e5-4dee-98e6-07f7579185b9.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [34 x 32] intentionally omitted <==
==> picture [149 x 44] intentionally omitted <==
October 9, 2018
To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Ref: Scrip Code: 532296
To, The Manager – Listing, National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051
Ref: Scrip Name: GLENMARK
Dear Sirs,
SUB: ANNOUNCEMENT OF SETTLEMENT OF THE REPURCHASE IN RESPECT OF THE COMPANY’S U.S.$200,000,000 2.00 PER CENT. RESETTABLE ONWARD STARTING EQUITY-LINKED SECURITIES DUE 2022
With respect to the above subject, please find enclosed herewith Announcement of Settlement of the Repurchase.
You are requested to take the same on record.
Thanking you
Yours faithfully, For Glenmark Pharmaceuticals Limited
HARISH VINAYAK Digitally signed by HARISH VINAYAK KUBER KUBER Date: 2018.10.09 19:12:58 +05'30' Harish Kuber Company Secretary Compliance Officer Encl: As above
Tel: 4018 9999 / 4018 9879 Fax: 4018 9986 (Legal & Secretarial Dept.)
Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [email protected]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA (THE “UNITED STATES”), INDIA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT.
9 October 2018
==> picture [42 x 42] intentionally omitted <==
Glenmark Pharmaceuticals Limited
( a company incorporated with limited liability under the laws of the Republic of India )
(the Company )
ANNOUNCEMENT OF SETTLEMENT OF THE REPURCHASE IN RESPECT OF THE COMPANY’S U.S.$200,000,000 2.00 PER CENT. RESETTABLE ONWARD STARTING EQUITY-LINKED SECURITIES DUE 2022
(ISIN: XS1426780125; COMMON CODE: 142678012) ( the “BONDS”)
On 28 September 2018, the Company announced the appointment of J.P. Morgan Securities plc and MUFG Securities Asia Limited (the Dealer Managers ) in relation to the purchase by the Dealer Managers of the Company’s Bonds in the open market for onward sale by the Dealer Managers to the Company (the Transaction ). A further announcement was made on 3 October 2018 with respect to the results of the Transaction.
The Company is pleased to announce that the settlement of the Transaction was completed on 5 October 2018. Following settlement of the Transaction, the Company has been informed by the Registrar that it has cancelled the Bonds that were purchased by the Dealer Managers pursuant to the Transaction and acquired by the Company on the Settlement Date. Accordingly, the aggregate principal amount of Bonds that remain outstanding as of the date hereof is U.S.$113,500,000.
Bondholders who have questions regarding the Transaction may contact the Dealer Managers.
DEALER MANAGERS
J.P. Morgan Securities plc 25 Bank Street Canary Wharf London E14 5JP United Kingdom
Telephone: +852 2800 1272 Email: [email protected]
MUFG Securities Asia Limited
11/F, AIA Central 1 Connaught Road Central Hong Kong
Telephone: +44 20 7577 4048/4218 (International) Telephone: +65 6232 7632 (Asia) Attention: Liability Management Group
Email: [email protected]
Disclaimer : This announcement contains important information which should be read carefully.
The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required by each of the Company and the Dealer Managers to inform themselves about and to observe, any such restrictions.
2